Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$AXSM Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.99 down -2.06% YoY • Reported revenue of $218.38M up 45.54% YoY • Axsome Therapeutics believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan, though no specific financial targets were provided.
7

Price since post

Full Details

Advertisement|Remove ads.